Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications

Clinical Microbiology and Infection

Volumn 22, Issue 9, 2016, Pages 815.e1-815.e3

  Liao, T L ^a,b   Chen, Y M ^a,b,c   Chen, D Y ^a,b,c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cryptococcal infection; Immunosuppressive medications; Outcomes; Rheumatoid arthritis; Risk factor

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CUTANEOUS CRYPTOCOCCOSIS; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ODDS RATIO; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; STEP WISE MULTIPLE REGRESSION; AGED; ARTHRITIS, RHEUMATOID; COMORBIDITY; COMPLICATION; FILOBASIDIELLA; MICROBIOLOGY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COMORBIDITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84994556179     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.05.030     Document Type: Article

References (14)

1. [1] Gavaldà, J., Meije, Y., Fortún, J., Roilides, E., Saliba, F., Lortholary, O., et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 20 (2014), 27–48.
2. [2] Antachopoulos, C., Walsh, T.J., Immunotherapy of Cryptococcus infections. Clin Microbiol Infect 18 (2012), 126–133.
3. [3] Nucci, M., Perfect, J.R., When primary antifungal therapy fails. Clin Infect Dis 46 (2008), 1426–1433.
4. [4] Baddley, J.W., Winthrop, K.L., Chen, L., Liu, L., Grijalva, C.G., Delzell, E., et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 73 (2014), 1942–1948.
5. [5] Kourbeti, I.S., Ziakas, P.D., Mylonakis, E., Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58 (2014), 1649–1657.
6. [6] Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.
7. [7] Pappas, P.G., Perfect, J.R., Cloud, G.A., Larsen, R.A., Pankey, G.A., Lancaster, D.J., et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33 (2001), 690–699.
8. [8] Husain, S., Wagener, M.M., Singh, N., Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 7 (2001), 375–381.
9. [9] Jarvis, J.N., Govender, N., Chiller, T., Park, B.J., Longley, N., Meintjes, G., et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) 11 (2012), 374–379.
10. [10] Phillips, P., Galanis, E., MacDougall, L., Chong, M.Y., Balshaw, R., Cook, V.J., et al. Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia. Clin Infect Dis 60 (2015), 1368–1376.
11. [11] Dixon, W.G., Abrahamowicz, M., Beauchamp, M.E., Ray, D.W., Bernatsky, S., Suissa, S., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 71 (2012), 1128–1133.
12. [12] Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
13. [13] Huffnagle, G.B., Toews, G.B., Burdick, M.D., Boyd, M.B., McAllister, K.S., McDonald, R.A., et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157 (1996), 4529–4536.
14. [14] Nestorov, I., Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 (2005), 12–18.